Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 11/20 | 0.44 |
| ▸ | CDK8 | P49336 | 11/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | MYLK | Q15746 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.44 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390185 | 0.84 | PDK2 (0.44) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL10264110 | 0.81 | L3MBTL1 (0.42) | PDK2L3MBTL1 | |
| SCHEMBL26714461 | 0.81 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL19020680 | 0.79 | ERCC5 (0.42) | PDK2ERCC5L3MBTL1 | |
| SCHEMBL10044956 | 0.79 | ALPI (0.50) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL18623452 | 0.79 | GSK3A (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL12020135 | 0.78 | CCNC (0.42) | CCNCCDK8PDK2JAK3L3MBTL1 | |
| SCHEMBL1703729 | 0.78 | CCNC (0.45) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL12492720 | 0.78 | CCNC (0.45) | CCNCCDK8FLT3MYLKAURKB | |
| SCHEMBL17605207 | 0.78 | CCNC (0.47) | CCNCCDK8FLT3MYLKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884874-B2 | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | KAINOS MEDICINE, INC. (KR) | 2018-02-06 | — | — | US | disclosed |
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE, INC. (KR) | 2017-06-22 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174702-A1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | BRDT, BRD4, BAZ2A | CCNC 208/4885CDK8 153/4885FLT3 1946/4885 |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | CCNC 1920/4885CDK8 1601/4885FLT3 627/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CCNC 633/4885CDK8 227/4885FLT3 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.